Zhi Tong Cai Jing·2025-12-01 02:34Core Viewpoint - JD Health (06618) has seen a significant increase in stock price due to rising demand for respiratory disease testing amid the flu season, with a focus on ensuring stable supply and innovative product offerings [1] Group 1: Stock Performance - JD Health's stock rose nearly 4% in early trading, currently up 3.19% at HKD 63, with a trading volume of HKD 149 million [1] Group 2: Market Demand and Response - The demand for flu test kits has surged, leading JD Health to collaborate with brand partners to launch a special supply guarantee mechanism to maintain stable prices [1] - JD Health's medical device department formed an IVD brand alliance with multiple companies to anticipate demand and manage inventory effectively [1] Group 3: Product Innovation - JD Health has launched an exclusive product, Oseltamivir granules (15mg x 18 bags), targeting children's flu treatment by addressing issues of dosage mismatch and medication waste [1] - The new product is designed for a standard 5-day treatment course, simplifying the medication process for parents and significantly reducing drug waste [1] - Since its launch, the product has seen an average daily sales growth rate exceeding 100%, becoming a preferred choice for families preparing for flu season [1]